Hansoh Pharmaceutical Group Co. Ltd. has released its 2024 annual report, detailing significant progress in drug research and development and operational excellence. The company reported that revenue from innovative drugs and collaborative products reached approximately 9,477 million, representing about 77.3% of the total revenue. The report highlights the company's strategic focus on innovation and internationalization, reinforced through international licensing collaborations. Furthermore, Hansoh Pharma maintained its AA rating in the MSCI ESG rating and ranked first in the Chinese pharmaceutical industry in the 2024 S&P Global Corporate Sustainability Assessment. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.